Navigation Links
Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
Date:11/5/2007

mcg and 1800 mcg. The most common adverse events were fatigue, headache, arthralgia (joint pain), myalgia (muscle pain), insomnia, nausea, cough, and pyrexia (fever). Discontinuation rates due to adverse events were: 4.2% for the 1200 mcg every four weeks group; 17.4% for the 900 mcg every two weeks group; 4.2% for the 1200 mcg every two weeks group; 9.1% for the 1500 mcg every two weeks group; and 18.2% for the 1800 mcg every two weeks group. Hematologic reductions stabilized by Week 8, were well managed with dose reductions, and returned to baseline following the completion of therapy.

"The results emerging from our Phase 2 program continue to support our belief that Albuferon could become an important therapeutic option for patients with chronic hepatitis C, including those that have failed prior therapy," said Mani Subramanian, M.D., Ph.D., Senior Director of Clinical Research, Infectious Diseases, HGS.

About Albuferon

Albuferon is a novel long-acting form of interferon alpha created by HGS using its proprietary albumin fusion technology. Albuferon results from the genetic fusion of human albumin and interferon alpha. Human albumin is the most prevalent naturally occurring blood protein in the human circulatory system, persisting in circulation in the body for more than 20 days. Research shows that genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of the proteins. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a number of cancers.

Albuferon is being developed by HGS and Novartis for the treatment of chronic hepatitis C under a worldwide co-development and commercialization agreement entered into in June 2006. HGS and Novartis will co-commercialize Albuferon in the United States and will share clinical development costs, U.S. commercialization costs and U.S. profits equally. Novartis will be responsible for commercialization in the rest of the
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... TOKIO , July 13, 2014 /PRNewswire/ ... Juli in Tokio ... der firmenseitigen Bemühungen zur Neuausrichtung seines Forschungsrahmenprogramms. ... umfassenden Überblick über die fortgeschrittenen klinischen Programme ... Das Ziel der Tagung bestand darin, aktuelle ...
(Date:7/13/2014)...  Eli Lilly and Company (NYSE: ... study in genetically engineered mice examining combination therapy ... N3pG and beta-secretase inhibitor BACE (LY2811376). Data results ... removing clumps of amyloid-beta protein in the brain ... to Alzheimer,s disease (AD) – than use of ...
(Date:7/11/2014)... /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced a new ... in portable vaporizers, which contains CBD, or cannabodiol. ... cannabidiol offers consumers a THC-free product made for ... technology. Photo - http://photos.prnewswire.com/prnh/20140711/126344 ... compounds which are currently known, two of which ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
... July 26 Halt Medical, Inc. announced ... been appointed to its Scientific Advisory Board.  Dr. Rubin ... to develop and implement comprehensive reimbursement strategies.  Dr. Rubin,s ... of medicine, government, and business. Currently, he is Clinical ...
... Reportlinker.com announces that a new market research report is available in its ... 2008 U.S. Diabetes Drug Delivery - ... http://www.reportlinker.com/p0236248/2008-US-Diabetes-Drug-Delivery---Patient-Perspective.html , ... This study encompasses feedback provided by U.S. diabetes patients ...
Cached Medicine Technology:Dr. Robert J. Rubin to Join Halt Board as Reimbursement Advisor 22008 U.S. Diabetes Drug Delivery - Patient Perspective 22008 U.S. Diabetes Drug Delivery - Patient Perspective 32008 U.S. Diabetes Drug Delivery - Patient Perspective 42008 U.S. Diabetes Drug Delivery - Patient Perspective 5
(Date:7/13/2014)... Illinois (PRWEB) July 13, 2014 Hope Palliative ... a monthly grief support group at the Tamarack Senior Living ... be held at 10:30 A.M. on the 3rd Wednesdays of ... 16th, 2014 at the Tamarack Community located at 55 S. ... all bereaved individuals and there is no cost for the ...
(Date:7/13/2014)... 13, 2014 According to The Peripheral ... a comprehensive program that teaches people how to deal ... without medications. This program also provides people with ... peripheral neuropathy , including numbness, prickling, burning, and intense ... that this home treatment program can help people eliminate ...
(Date:7/13/2014)... 2014 Recently, iFitDress.com, one of the ... occasion outfits, has added a new selection of beautiful ... company has launched a promotion for these evening gowns. ... iFitDress.com is now providing thousands of graceful gowns in ... in Britain, America, France, Italy and many other countries. ...
(Date:7/12/2014)... a well-known wedding dress manufacturer and retailer, has added a ... its product line. In addition, the company has launched a ... more benefits for its loyal fans. All its brand ... 72% off. , As a leader in the garment industry, ... a good place for ladies who want to purchase charming ...
(Date:7/12/2014)... 12, 2014 The Chicken Egg ... past five years, buoyed by stable demand for industry ... system. “Eggs are a relatively affordable staple for most ... consumption generally grows in line with the size of ... Furthermore, demand for new specialty egg products with enriched ...
Breaking Medicine News(10 mins):Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:New and Beautiful Evening Dresses Unveiled by iFitDress.com 2Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3
... have found that a cancer of the lymphatic system, ... produced by a malaria parasite. ,The ... Arnaud Chene and Qijun Chen at the Karolinska Institute ... a large number of children in equatorial Africa causing ...
... India continued to reel under a scorching June sun with ... and Sri Ganganagar in Rajasthan at a searing 46.6 degrees. ... ,Following close behind Sri Ganganagar was Amritsar ... ,"It is summer time and almost all cities in ...
... enough vitamin D, a fact that may put them ... landmark study conducted by Creighton University School of Medicine. ... healthy, postmenopausal women from rural eastern Nebraska.* Participants taking ... nearly three times the U.S. governments Recommended Daily Amount ...
... Human embryonic stem cells (hESC), those very young cells that ... more specialized, contributing to the workings of a wide ... such as Parkinsons is slow to be realized because of ... deriving hESC lines. Additionally, its a politically charged issue in ...
... the chest cavity from the abdominal cavity, is critical ... as congenital diaphragmatic hernia (CDH), results from failure of ... to migrate into the chest cavity. Abnormal lung development, ... fact is the major predictor of morbidity and mortality. ...
... in the last 13 years, but their long-term safety remains ... ,A report in The British Journal of Clinical Pharmacology notes ... meaning consultants have no official guidance on doses to refer ... to estimate a safe and effective dose based on the ...
Cached Medicine News:Health News:Vitamin D Reduces Cancer Risk 2Health News:Dartmouth Professor Makes Case for Ethically Universal Stem Cell Lines 2Health News:Understanding and Treating Congenital Diaphragmatic Hernia 2Health News:Understanding and Treating Congenital Diaphragmatic Hernia 3Health News:Understanding and Treating Congenital Diaphragmatic Hernia 4Health News:UK Researchers Call for Safety Studies of New Anti-epilepsy Drugs for Children 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: